Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.5450
-0.0175 (-3.11%)
Apr 28, 2025, 4:00 PM EDT - Market closed

Company Description

Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility.

Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products.

The company was founded in 2019 and is based in Naples, Florida.

Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals logo
Country United States
Founded 2019
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Andrew Regan

Contact Details

Address:
4581 Tamiami Trail North, Suite 200
Naples, Florida 34103
United States
Phone (646)-491-9132
Website conduitpharma.com

Stock Details

Ticker Symbol CDT
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001896212
CUSIP Number 20678X106
ISIN Number US20678X1063
Employer ID 87-3272543
SIC Code 2834

Key Executives

Name Position
Dr. Andrew Regan Founder, Chief Executive Officer and Director
James Bligh Interim Chief Financial Officer and Director
Dr. David Joszef Tapolczay Head of Strategy and Licensing
Dr. Joanne M. Holland Chief Scientific Officer

Latest SEC Filings

Date Type Title
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 25, 2025 8-K Current Report
Apr 22, 2025 S-3 Registration statement under Securities Act of 1933
Apr 16, 2025 PRE 14A Other preliminary proxy statements
Apr 16, 2025 8-K Current Report
Apr 10, 2025 SCHEDULE 13G/A Filing
Apr 4, 2025 8-K Current Report
Apr 2, 2025 8-K/A [Amend] Current report
Apr 1, 2025 8-K Current Report
Mar 28, 2025 10-K Annual Report